Apixaban and Rivaroxaban in Patients With Acute Venous Thromboembolism

Agnelli, 2013, Oral apixaban for the treatment of acute venous thromboembolism, N Engl J Med, 369, 799, 10.1056/NEJMoa1302507 Bauersachs, 2010, Oral rivaroxaban for symptomatic venous thromboembolism, N Engl J Med, 363, 2499, 10.1056/NEJMoa1007903 Büller, 2012, Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, N Engl J Med, 366, 1287, 10.1056/NEJMoa1113572 Agnelli, 2013, Apixaban for extended treatment of venous thromboembolism, N Engl J Med, 368, 699, 10.1056/NEJMoa1207541 Weitz, 2017, Rivaroxaban or aspirin for extended treatment of venous thromboembolism, N Engl J Med, 376, 1211, 10.1056/NEJMoa1700518 Prins, 2013, Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies, Thromb J, 11, 21, 10.1186/1477-9560-11-21 Schulman, 2017, NOACs for treatment of venous thromboembolism in clinical practice, Thromb Haemost, 117, 1317, 10.1160/TH17-01-0065 Beyer-Westendorf, 2018, What have we learned from real-world NOAC studies in venous thromboembolism treatment?, Thromb Res, 163, 83, 10.1016/j.thromres.2018.01.034 Bott-Kitslaar, 2016, Efficacy and safety of rivaroxaban in patients with venous thromboembolism and active malignancy: a single-center registry, Am J Med, 129, 615, 10.1016/j.amjmed.2015.12.025 Janczak, 2018, Rivaroxaban and apixaban for initial treatment of acute venous thromboembolism of atypical location, Mayo Clin Proc, 93, 40, 10.1016/j.mayocp.2017.10.007 Kearon, 2012, Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest, 141, e419S, 10.1378/chest.11-2301 2014, 24 Kearon, 2016, Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report, Chest, 149, 315, 10.1016/j.chest.2015.11.026 Vedovati, 2015, Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis, Chest, 147, 475, 10.1378/chest.14-0402 Raskob, 2018, Edoxaban for the treatment of cancer-associated venous thromboembolism, N Engl J Med, 378, 615, 10.1056/NEJMoa1711948 Jiménez, 2010, Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism, Arch Intern Med, 170, 1383, 10.1001/archinternmed.2010.199 Girard, 2017, Reproducibility of clinical events adjudications in a trial of venous thromboembolism prevention, J Thromb Haemost, 15, 662, 10.1111/jth.13626 Schulman, 2005, Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients, J Thromb Haemost, 3, 692, 10.1111/j.1538-7836.2005.01204.x Kaatz, 2015, Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH, J Thromb Haemost, 13, 2119, 10.1111/jth.13140 Ashrani, 2016, Risk factors for incident venous thromboembolism in active cancer patients: a population based case-control study, Thromb Res, 139, 29, 10.1016/j.thromres.2016.01.002